Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.

ABSTRACT:

Introduction

The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data.

Methods

We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer.

Results

Twelve clinical trials and 2 case reports were identified in our study.

Conclusion

The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant set

SUBMITTER: Kyriazoglou A 

PROVIDER: S-EPMC8914190 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature